Prevention and regression of atopic dermatitis by ointment containing NF-kB decoy oligodeoxynucleotides in NC/Nga atopic mouse model

Gene Therapy

Volumn 9, Issue 18, 2002, Pages 1221-1229

  Nakamura, H ^a   Aoki, M ^a   Tamai, K ^b   Oishi, M ^c   Ogihara, T ^a   Kaneda, Y ^a   Morishita, R ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b HIROSAKI UNIVERSITY   (Japan)

^c OSAKA UNIVERSITY HOSPITAL   (Japan)

Author keywords

Atopic dermatitis; Decoy; Gene therapy; Mast cells; NFkB

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; OLIGODEOXYNUCLEOTIDE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTICLE; ATOPIC DERMATITIS; CELL MIGRATION; CONTROLLED STUDY; DERMIS; DRUG FORMULATION; GENETIC TRANSFECTION; HISTOPATHOLOGY; MALE; MAST CELL; MOUSE; MOUSE STRAIN; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; OINTMENT; PRIORITY JOURNAL; REMISSION; SCORING SYSTEM; TREATMENT OUTCOME;

ADMINISTRATION, CUTANEOUS; ANIMALS; DERMATITIS, ATOPIC; GENE THERAPY; IN SITU NICK-END LABELING; MALE; MAST CELLS; MICE; MICE, INBRED STRAINS; MODELS, ANIMAL; NF-KAPPA B; OINTMENTS; SKIN ABSORPTION; TRANSFECTION;

ANIMALIA;

EID: 0036740350     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3301724     Document Type: Article

References (33)

1. Pastore S et al. Pathogenetic mechanisms of atopic dermatitis. Arch Immunol Ther Exp (Warsz) 2000; 48: 497-504.
2. Leung DYM. Atopic dermatitis: new insights and opportunities for therapeutic intervention. J Allergy Clin Immunol 2000; 105: 860-876.
3. Romangnani S. The role of lymphocytes in allergic disease. J Allergy Clin Immunol 2000; 105: 399-408.
4. Akdis CA, Akdis M, Trautmann A, Blaser K. Immune regulation in atopic dermatitis. Curr Opin Immunol 2000; 12: 641-646.
5. Wollenberg A, Bieber T. Atopic dermatitis: from the genes to skin lesions. Allergy 2000; 55: 205-213.
6. Leung DYM. Atopic dermatitis: immunobiology and treatment with immune modulators. Clin Exp Immunol 1997; 107: 25-30.
7. Makarov SS. NFkB as a therapeutic target in chronic inflammation: recent advances. Mol Med Today 2000; 6: 441-448.
8. Paul HL. Activators and target genes of Rel/NF-kB transcription factors. Oncogene 1999; 18: 6853-6866.
9. Morishita R, Higaki J, Tomita N, Ogihara T. Application of transcription factor 'decoy' strategy as means of gene therapy and study of gene expression in cardiovascular disease. Circ Res 1990; 82: 1023-1028.
10. Morishita R, Aoki M, Kaneda Y. Oligonucleotides-based gene therapy for cardiovascular disease: are oligonucleotides therapeutics novel cardiovascular drugs? Current Drug Targets 2000; 1: 15-23.
11. Morishita R et al. In vivo transfection of cis element 'decoy' against nuclear factor-kB binding site prevents myocardial infarction. Nat Med 1997; 3: 894-899.
12. Tomita T et al. Suppressed severity of collagen-induced arthritis by in vivo transfection of nuclear factor kB decoy oligodeoxynucleotides as a gene therapy. Arthritis Rheum 1999; 42: 2532-2542.
13. Kawamura I et al. Intratumoral injection of oligonucleotides to the NF-kappaB binding site inhibits cachexia in a mouse tumor model. Gene Therapy 1999; 6: 91-97.
14. Tomita N et al. In vivo administration of a nuclear factor-kB decoy suppresses experimental crescentic glomerulonephritis. J Am Soc Nephrol 2000; 11: 1244-1252.
15. Kawamura I et al. Intravenous injection of oligonucleotides to the NF-kappaB binding site inhibits hepatic metastasis of M5076 reticulosarcoma in mice. Gene Therapy 2001; 8: 905-912.
16. Matsuda H et al. Development of atopic dermatitis-like skin lesion with IgE hyperproduction in NC/Nga mice. Int Immunol 1997; 107: 461-466.
17. Suto H et al. NC/Nga mice: a mouse model for atopic dermatitis. Int Arch Allergy Immunol 1999; 120: (Suppl. 1) 70-75.
18. Sugiura K et al. The study on the role of Myocoptes musculinus (kekuidani) on the skin eruptions of the atopic model mice (NC mice). Environ Dermatol 2000; 7: 52-60.
19. Mehta RC et al. Intercellular adhesion molecule-1 suppression in skin by topical delivery of anti-sense oligonucleotides. J Invest Dermatol 2000; 115: 805-812.
20. Tomita N et al. Transcription factor decoy for nuclear factor-kB inhibits tumor necrosis factor-induced expression of interleukin-6 and intercellular adhesion molecule-1 in endothelial cells. J Hypertens 1998; 16: 993-1000.
21. Yoshikawa H, Tasaka K. Suppression of mast cell activation by glucocorticoid. Arch Immunol Ther Exp (Warsz) 2000; 48: 487-495.
22. Nakagawa H et al. Tacrolimus ointment for atopic dermatitis. Lancet 1994; 344: 883.
23. Hiroi J et al. Effect of tacrolimus hydrate (FK506) ointment on spontaneous dermatitis in NC/Nga mice. Jpn J Pharmacol 1998; 76: 175-183.
24. Trautman A, Akdis M, Blaser K, Akdis CA. Role of dysregulated apoptosis in atopic dermatitis. Apoptosis 2000; 5: 425-429.
25. Klement JF et al. IkappaBalpha deficiency results in a sustained NF-kappaB response and severe widespread dermatitis in mice. Mol Cell Biol 1996; 16: 2341-2349.
26. Barton D, HogenEsch H, Weih F. Mice lacking the transcription factor RelB develop T cell-dependent skin lesions similar to human atopic dermatitis. Eur J Immunol 2000; 30: 2323-2332.
27. Xia Y et al. RelB modulation of IkappaBalpha stability as a mechanism of transcription suppression of interleukin-1alpha (IL-1alpha), IL-1beta, and tumor necrosis factor alpha in fibroblasts. Mol Cell Biol 1999; 19: 7688-7696.
28. Roque F et al. Safety of intracoronary administration of c-myc antisense oligomers after percutaneous transluminal coronary angioplasty (PTCA). Antisense Nucleic Acid Drug Dev 2001; 2: 99-106.
29. Cunningham CC. A phase I trial of c-Raf kinase antisense oligonucleotide ISIS 5132 administered as a continuous intravenous infusion in patients with advanced cancer. Clin Cancer Res 2000; 6: 1626-1631.
30. Neish AS et al. Functional analysis of the human vascular cell adhesion molecule 1 promoter. J Exp Med 1992; 176: 1583-1593.
31. Kittelberger R, Davis PF, Stehbens WE. An improved immunofluorescence technique for the histological examination of blood vessel tissue. Acta Histochem 1989; 86: 137-142.
32. Morishita R et al. Pharmacokinetics of antisense oligodeoxyribonucleotides (cyclin B1 and CDC 2 kinase) in the vessel wall in vivo: enhanced therapeutic utility for restenosis by HVJ-liposome delivery. Gene 1994; 149: 13-19.
33. Gavrieli Y, Sherman Y, Ben-Sasson SA. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 1992; 119: 493-501.